RepliCel Life Sciences Inc (REPCF)
0.0428
0.00 (0.00%)
USD |
OTCM |
Apr 18, 16:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 2.785M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -61.05% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 8.989 |
Price to Book Value | -- |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -0.0062 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 97.73% |
Profile
RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from Licensing fees. |
URL | https://www.replicel.com |
Investor Relations URL | http://replicel.com/investors/investor-hub/ |
HQ State/Province | British Columbia |
Sector | Health Care |
Industry | Life Sciences Tools & Services |
Equity Style | Small Cap/Value |
Next Earnings Release | N/A |
Last Earnings Release | N/A |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from Licensing fees. |
URL | https://www.replicel.com |
Investor Relations URL | http://replicel.com/investors/investor-hub/ |
HQ State/Province | British Columbia |
Sector | Health Care |
Industry | Life Sciences Tools & Services |
Equity Style | Small Cap/Value |
Next Earnings Release | N/A |
Last Earnings Release | N/A |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |